KANRENOL ® is a potassium canrenoate based drug
THERAPEUTIC GROUP: Diuretics / Antialdosteronic diuretics
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications KANRENOL ® Potassium Canrenoate
KANRENOL ® is indicated in the treatment of edematous conditions of various origins, due to congestive heart failure, ascitic cirrhosis, nephrotic syndrome.
The antialdosteronic action of KANRENOL ® also guarantees therapeutic efficacy in case of primary and secondary hyperaldosteronism with consequent edema.
KANRENOL ® can also be used in the treatment of arterial hypertension when other therapies are not particularly effective.
Mechanism of action KANRENOL ® Potassium canrenoate
Potassium canrenoate, the active ingredient of KANRENOL ® following oral administration is effectively absorbed with a plasma peak of canrenone (active form of the active ingredient) around the third, fourth hour, and with a prolonged half-life for several hours.
At renal level, canrenone is able to compete with aldosterone for binding to the respective receptors, expressed in the distal convoluted tubule and in the collecting duct. The competitive action takes the form of a reduction in the reabsorption of sodium and chlorine, saving potassium from urinary excretion. For this reason and for a therapeutic efficacy carried out even at low doses, potassium canrenoate is more indicated than other diuretics in long-term therapeutic treatment.
Once its action is over, the canrenone is eliminated in equal parts at renal and intesintal level.
Studies carried out and clinical efficacy
1 POTASSIUM CANRENOATE AND CIRCULAR VARMS
120 patients with ascites were treated with potassium canrenoate at 100mg / day. Although the therapy was well tolerated and free of clinically relevant side effects, the individual incidence of esophageal varices in the treated patients was not reduced, while there was a decline in the worsening of the conditions and the accumulation of these events during one year of treatment.
2. POTASSIUM CANRENATO AND ASCITES
The study shows that potassium canrenoate therapy is effective for the treatment of the ascitic condition already at doses of 200mg / day. For patients not responsive to this therapy, the dose was doubled and only at a later time the concomitant administration of furosemide. The results obtained show that potassium canrenoate was sufficient in almost 80% of treated patients, whereas synergistic therapy was necessary only for a small group of non-responders.
3. CARDIOPROTECTIVE EFFECT OF ANTI-ALDOSTERONS
Studies carried out on animal models of cardiac ischemia / reperfusion (typical condition during myocardial infarction) have demonstrated a particular efficacy of antialdosteronics in reducing the induced tissue damage. This study suggests a possible use of antialdosteronics for the treatment of acute myocardial infarction.
Method of use and dosage
KANRENOL ® 25mg / 100mg / 200mg tablets of potassium canrenoate: we recommend taking 1 tablet a day, depending on the type and severity of the pathological condition. Therefore, the dosage should necessarily be formulated by the doctor, after a careful evaluation of the patient's physiopathological conditions.
KANRENOL ® potassium canrenoate 200mg bottles: it is recommended to take 1 - 3 falcons a day, for slow intravenous infusion or infusion. Also in this case the specific dosage must be formulated by the doctor based on the patient's condition, and the administration carried out by trained health personnel.
IN EVERY CASE, BEFORE TAKING KANRENOL ® Potassium Canrenoato - THE PRESCRIPTION AND CONTROL OF ITS OWN DOCTOR IS NECESSARY.
Warnings KANRENOL ® Potassium Canrenoate
As with the other drugs belonging to this pharmacotherapeutic group, it is advisable to check the blood levels of sodium, potassium and chlorine before taking KANRENOL ®. Monitoring of these parameters should be prolonged even during therapeutic intervention, with particular care in patients undergoing surgery.
The particular biological action of the canrenone, which saves potassium, makes it possible to avoid a diet rich in this trace element during the therapeutic course.
Pediatric use must be carried out under strict medical supervision and in case of real need.
The use of KANRENOL ® does not interfere with normal driving skills or use of machinery, however unpredictable and possible hypotensive episodes, especially in the case of inadequate dosage, could reduce the patient's perceptive and reactive abilities.
PREGNANCY AND BREASTFEEDING
KANRENOL ® can be administered during pregnancy, only in cases of real need and only under strict medical supervision. The property of canrenone to be secreted with breast milk obliges the mother to suspend breastfeeding during therapy.
Interactions
KANRENOL ® can interact with:
- Ganglioplegici of various kinds, strengthening their effects;
- Hypertensive, with increased diuretic effect;
- Acetylsalicylic acid and derivatives, with a significant reduction in the diuretic efficacy of canrenone;
- Potassium salts, with possible hyperkalemia.
Contraindications KANRENOL ® Potassium canrenoato
KANRENOL ® is contraindicated in case of hypersensitivity to one of its components, in conditions of electrolyte imbalance (hyperkalemia and hyponatremia), acute and chronic renal failure, and anuria.
Undesirable effects - Side effects
KANRENOL ® when administered at therapeutic doses established on the actual need of the patient, is safer than diuretics of other nature, recording among other things rarely side effects such as nausea, cramps, abdominal pain and drowsiness.
In case of hypersensitivity to one of the components of KANRENOL ® or in case of concomitant administration of structurally similar drugs, it is possible to observe thermal elevations, gynecomastia, rashes, localized redness, menstrual irregularities and hirsutism. All the aforementioned effects tend to fall once the therapy has been suspended.
Note
KANRENOL ® is salable only under medical prescription.
The use of KANRENOL ® should always take place after consulting your doctor.
The indiscriminate use of KANRENOL ® between athletes and non-athletes, in the search for the loss of a few pounds, exposes the body to serious side effects. Furthermore, it is always advisable to reiterate that weight loss is dictated by the elimination of liquids and salts and not by a real weight loss effect, understood as a loss of fat mass.
Therefore KANRENOL ® is classified as a DOPANTI substance.
